However, the strength of IL-6 signals in CD4+ T cells versus tumor cells could differ, and targeting IL-6 to inhibit GBM tumor growth may need to consider its impact on CD4+ T cells, which needs to be further explored. The gene discussed is CD4; the disease is neoplasm.